echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Suoyuan Biotech and Kaijie have reached a cooperation to help the development of precision tumor therapy

    Suoyuan Biotech and Kaijie have reached a cooperation to help the development of precision tumor therapy

    • Last Update: 2021-12-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ArticleMedicine Guanlan

    On December 10th, Suoyuan Bio and QIAGEN jointly announced that the two parties will cooperate on a global scale to develop blood-based companion diagnostics (CDx) products to detect Suoyuan Bio’s newly discovered pharmacogenomic biomarkers.


    DB102 is a small-molecule serine/threonine kinase inhibitor with "first-in-class" potential acquired by Suoyuan Biotech from Eli Lilly and Company, which acts on PKCβ, PI3K and AKT and other tumor fields Key tumor targets


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.